Table 3.
Prognostic factors for subsequent recurrence after previous LR or RR
| Characteristic | Event after LR (n = 362, 102 events) | Event after RR (n = 148, 74 events) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariable | Multivariable | Univariable | Multivariable | |||||||||
| HR | 95% CI | p | HR | 95% CI | p | HR | 95% CI | p | HR | 95% CI | p | |
| Age (years) | ||||||||||||
| <40 | Ref. | Ref | Ref | Ref | ||||||||
| 40–49 | 0.9 | 0.44–1.85 | 0.772 | 1.06 | 0.50–2.24 | 0.889 | 1 | 0.43–2.31 | 0.999 | 0.89 | 0.38–2.11 | 0.793 |
| 50–74 | 0.83 | 0.43–1.58 | 0.567 | 1.04 | 0.52–2.09 | 0.904 | 1.19 | 0.61–2.35 | 0.609 | 1.87 | 0.90–3.88 | 0.093 |
| ≥75 | 1.75 | 0.80–3.83 | 0.158 | 1.47 | 0.62–3.46 | 0.378 | 0.21 | 0.03–1.67 | 0.141 | 0.29 | 0.04–2.29 | 0.240 |
| Tumour size | ||||||||||||
| ≤2 cm | Ref. | Ref | Ref | Ref | ||||||||
| 2–5 cm | 3.28 | 2.17–4.95 | <.001 | 3.01 | 1.91–4.74 | 0.000 | 1.04 | 0.65–1.67 | 0.865 | 0.83 | 0.50–1.38 | 0.467 |
| >5 cm | 7.85 | 3.29–18.74 | <.001 | 2.60 | 0.95–7.10 | 0.062 | 1.34 | 0.41–4.38 | 0.625 | 1.64 | 0.49–5.54 | 0.426 |
| Grade | ||||||||||||
| I | Ref. | Ref | Ref | |||||||||
| II | 2.31 | 1.06–5.04 | 0.036 | 1.25 | 0.55–2.83 | 0.595 | 0.91 | 0.41–2.04 | 0.825 | |||
| III | 5.72 | 2.71–12.07 | <.001 | 3.31 | 1.49–7.37 | 0.003 | 1.04 | 0.48–2.23 | 0.922 | |||
| Lymph nodes | ||||||||||||
| Negative | Ref. | Ref | Ref | |||||||||
| 1–3 positive | 2.98 | 1.92–4.64 | <.001 | 1.94 | 1.20–3.14 | 0.007 | 1.07 | 0.62–1.82 | 0.816 | |||
| >3 positive | 7.03 | 4.05–12.21 | <.001 | 3.23 | 1.65–6.30 | 0.001 | 2.25 | 1.01–4.98 | 0.047 | |||
| Hormone status | ||||||||||||
| ER&PR− | Ref. | Ref* | Ref | Ref | ||||||||
| ER/PR+ | 0.41 | 0.27–0.62 | <.001 | 0.6 | 0.41–0.96 | 0.032 | 0.58 | 0.36–0.92 | 0.021 | 0.6 | 0.31–1.13 | 0.111 |
| Histology | ||||||||||||
| Ductal | Ref. | Ref | Ref | |||||||||
| Lobular | 0.77 | 0.42–1.46 | 0.436 | 0.73 | 0.37–1.42 | 0.352 | 1.56 | 0.71–3.43 | 0.266 | |||
| Other | 0.15 | 0.04–0.62 | 0.009 | 0.14 | 0.03–0.60 | 0.008 | 1.09 | 0.40–3.01 | 0.867 | |||
| Multifocality | ||||||||||||
| No | Ref. | Ref | Ref | Ref | ||||||||
| Yes | 0.98 | 0.52–1.87 | 0.961 | 1.20 | 0.76–2.01 | 0.398 | 1.07 | 0.47–0.89 | 0.880 | 1.59 | 0.66–3.82 | 0.297 |
| Surgery type | ||||||||||||
| BCS | Ref. | Ref | ||||||||||
| Mastectomy | 2.67 | 1.79–3.97 | <.001 | 0.87 | 0.55–1.39 | 0.557 | ||||||
| Residual disease | ||||||||||||
| No | Ref. | Ref | ||||||||||
| Microscopic | 0.31 | 0.04–2.17 | 0.236 | 0.79 | 0.19–1.17 | 0.743 | ||||||
| Chemotherapy | ||||||||||||
| No | Ref. | Ref | ||||||||||
| Yes | 3.07 | 2.07–4.54 | <.001 | 1.1 | 0.68–1.76 | 0.696 | ||||||
| Radiation therapy | ||||||||||||
| No | Ref. | Ref | ||||||||||
| Yes | 0.58 | 0.39–0.86 | 0.007 | 1.56 | 0.98–2.46 | 0.058 | ||||||
| Endocrine therapy | ||||||||||||
| No | Ref. | Ref* | Ref | Ref | ||||||||
| Yes | 1.94 | 1.30–2.91 | 0.001 | 1.60 | 1.08–2.42 | 0.020 | 0.98 | 0.60–1.59 | 0.930 | 1.3 | 0.73–2.31 | 0.381 |
| DFI (years) | ||||||||||||
| 0–1.9 | Ref. | Ref | Ref* | |||||||||
| 2.0–3.9 | 0.58 | 0.37–0.91 | 0.02 | 0.98 | 0.57–1.68 | 0.930 | 0.97 | 0.59–1.59 | 0.899 | |||
| 4.0–5.9 | 0.35 | 0.19–0.65 | <.001 | 0.7 | 0.36–1.36 | 0.298 | 2.07 | 1.04–4.16 | 0.040 | |||
| 6.0–7.9 | 0.15 | 0.05–0.41 | <.001 | 0.58 | 0.25–1.33 | 0.198 | 3.94 | 1.42–10.96 | 0.009 | |||
| 8.0–10.0 | 0.29 | 0.10–0.82 | 0.02 | 0.25 | 0.03–1.83 | 0.170 | 4.34 | 0.24–76.81 | 0.317 | |||
| Surgery of recurrence | ||||||||||||
| No | Ref. | Ref | Ref | Ref | ||||||||
| Yes | 0.33 | 0.20–0.55 | <.001 | 0.40 | 0.21–0.75 | 0.005 | 0.52 | 0.33–0.82 | 0.005 | 0.42 | 0.26–0.70 | 0.001 |
| Chemotherapy of recurrence | ||||||||||||
| No | Ref. | Ref | Ref | |||||||||
| Yes | 1.03 | 0.60–1.76 | 0.92 | 0.66 | 0.37–1.19 | 0.170 | 1.31 | 0.83–2.08 | 0.245 | |||
| Radiation therapy of recurrence | ||||||||||||
| No | Ref. | Ref | Ref | |||||||||
| Yes | 2.02 | 1.37–2.98 | <.001 | 1.51 | 0.96–2.39 | 0.076 | 1.4 | 0.87–2.26 | 0.169 | |||
| Endocrine therapy of recurrence | ||||||||||||
| No | Ref. | Ref | Ref | |||||||||
| Yes | 0.69 | 0.46–1.04 | 0.07 | 0.61 | 0.38–0.98 | 0.040 | 0.64 | 0.36–1.17 | 0.148 | |||
LR local recurrence, RR regional recurrence, HR hazard ratio, CI confidence interval, BCS breast conserving surgery, PR progesterone receptor, Ref. reference group, DFI disease-free interval
* time-dependent variable in analysis